{"filing":{"accession_number":"0001213900-26-084256","cik":"0001944552","ticker":"ANL","company_name":"Adlai Nortye Ltd.","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"ea0299478-6k_adlai.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1944552/000121390026084256/ea0299478-6k_adlai.htm"},"events":[{"id":23020,"run_id":20839,"accession_number":"0001213900-26-084256","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a material clinical development milestone: submission of a Clinical Trial Notification (CTN) to Australia's TGA and HREC approval to commence a Phase I clinical trial for AN4035, a first-in-class pan-RAS(ON) ADC. The company also notes that IND submissions to the U.S. FDA and China NMPA are in process, with patient dosing expected in H2 2026. For a clinical-stage biopharmaceutical company, advancement of a lead therapeutic candidate into human clinical trials is a material operational and strategic event that would affect a reasonable investor's assessment of the company's progress and pipeline value.","company_name":"Adlai Nortye Ltd.","ticker":"ANL","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23157,"accession_number":"0001213900-26-084256","item_number":"EX-99.1","item_title":"ea029947801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material clinical development milestone: submission of a Clinical Trial Notification (CTN) to Australia's TGA and HREC approval to commence a Phase I clinical trial for AN4035, a first-in-class pan-RAS(ON) ADC. The company also notes that IND submissions to the U.S. FDA and China NMPA are in process, with patient dosing expected in H2 2026. For a clinical-stage biopharmaceutical company, advancement of a lead therapeutic candidate into human clinical trials is a material operational and strategic event that would affect a reasonable investor's assessment of the company's progress and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:19:38.935267+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23157,"accession_number":"0001213900-26-084256","item_number":"EX-99.1","item_title":"ea029947801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material clinical development milestone: submission of a Clinical Trial Notification (CTN) to Australia's TGA and HREC approval to commence a Phase I clinical trial for AN4035, a first-in-class pan-RAS(ON) ADC. The company also notes that IND submissions to the U.S. FDA and China NMPA are in process, with patient dosing expected in H2 2026. For a clinical-stage biopharmaceutical company, advancement of a lead therapeutic candidate into human clinical trials is a material operational and strategic event that would affect a reasonable investor's assessment of the company's progress and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:19:38.935267+00:00","company_name":"Adlai Nortye Ltd.","ticker":"ANL","filing_date":"2026-08-03"}]}